Akhondzadeh 2003.

Methods	A 4‐week randomised, double‐blind, clinical trial, parallel‐design where children with ADHD are randomised to methylphenidate or selegiline
Participants	Number of participants screened: not stated Number of participants included: 28 Number of participants randomised: selegiline: 14; methylphenidate: 14 Number participants followed‐up in each arm: selegiline: 13; methylphenidate: 10 Number of withdrawals in each arm: selegiline: 1; methylphenidate: 4 Methylphenidate group Diagnosis of ADHD: DSM‐IV (subtype: combined) Age: mean 7.37 years old (SD 1.59) IQ: above 70 Sex: 10 males, 4 females Methylphenidate‐naïve: 100% Ethnicity: Persian Country: Iran Setting: outpatient clinic Comorbidity: not stated Comedication: none Sociodemographics: not stated Inclusion criteria DSM‐IV IQ > 70 Parents and children had to be willing to comply with all requirements of the study Minimum score of 20 on the teacher and parent ADHD rating scale Exclusion criteria Previously diagnosed with a psychiatric disorder Clinically significant chronic medical condition, incl. a past history of cardiovascular disease, organic brain disorder, or seizures Current abuse or dependence on drugs within 6 months Current treatment with psychotropic medications
Interventions	Participants were randomly assigned to receive treatment using either selegiline 5 mg/day (under 5 years of age) and 10 mg/day (over 5 years of age) or methylphenidate 1 mg/kg/day for a 4‐week double‐blind clinical trial Methylphenidate type: not stated Administration schedule: not stated Titration period: not stated Treatment compliance: not stated
Outcomes	Non‐serious adverse events: Anxiety: 3 Decreased appetite: 5 Increased appetite: 0 Difficulty falling a sleep: 4 Abdominal pain: 3 Nausea: 2 Headache: 6
Notes	Sample calculation: not stated Any withdrawals due to adverse events: not stated Ethics approval: not explicitly stated but inferred: informed consent (parent and children) was received before the administration of any study procedure or dispensing of study medication in accordance with the ethical standards of the investigative site's institutional review board and with the Helsinki Declaration of 1975, as revised in 2000 Funding/vested interests/authors' affiliations: not stated Key conclusions of the study authors: the results of the study must be considered preliminary, but they do suggest that selegiline may be beneficial in the treatment of ADHD. In addition, a tolerable side effect profile may be considered as one of the advantages of selegiline in the treatment of ADHD Supplemental information requested from the study authors twice in June 2013 with no answer